GlassScriptPhysician profile
Sarah Biggs
NPI 1376079202
$3,524.28
in general payments reported to CMS, 2019-2025
23 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.91 · 2021: $134 · 2022: $640 · 2023: $690 · 2024: $724 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,559 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,558.77 |
| Education | $179.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $760.94 | 2021-2025 | Dupixent |
| Genzyme Corporation | $511.18 | 2022-2025 | |
| Glaxosmithkline, LLC. | $434.25 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $325.06 | 2022-2025 | Airsupra, Fasenra |
| Genentech USA, INC. | $286.57 | 2022-2025 | Xolair |
| Csl Behring | $202.31 | 2022-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $194.36 | 2022-2025 | Cuvitru, Takhzyro |
| Novartis Pharmaceuticals Corporation | $133.30 | 2025 | |
| Abbvie INC. | $111.40 | 2022-2023 | Rinvoq |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Amgen INC. | $78.75 | 2022-2025 | Tezspire |
| Blueprint Medicines Corporation | $60.01 | 2023-2024 | Ayvakit |
| Pharming Healthcare, INC. | $52.11 | 2022-2025 | Ruconest |
| Aimmune Therapeutics, INC. | $51.18 | 2022 | |
| Incyte Corporation | $46.62 | 2023 | Opzelura |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greer Laboratories, INC. | $36.34 | 2022-2025 | Palforzia |
| Ars Pharmaceuticals Operations, INC. | $29.38 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $24.63 | 2022 | |
| Alk-Abello, INC | $22.92 | 2021 | |
| Lilly USA, LLC | $21.31 | 2025 | Ebglyss |
| Pfizer INC. | $14.88 | 2023 | |
| Galderma Laboratories, L.P. | $14.87 | 2025 | Nemluvio |
| Sobi, INC | $12.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Biggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.